These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 22085375)

  • 1. Long-term follow-up of phase II trial of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer.
    Tokuda Y; Takigawa N; Kozuki T; Kamei H; Bessho A; Tada A; Hotta K; Katsui K; Kanazawa S; Tanimoto M; Kiura K
    Acta Oncol; 2012 Apr; 51(4):537-40. PubMed ID: 22085375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction chemotherapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study.
    Aydiner A; Sen F; Saglam EK; Oral EN; Eralp Y; Tas F; Toker A; Dilege S
    Clin Lung Cancer; 2011 Sep; 12(5):286-92. PubMed ID: 21729649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent chemoradiation therapy with docetaxel/cisplatin followed by docetaxel consolidation therapy in inoperable stage IIIA/B non-small-cell lung cancer: results of a phase I study.
    Huber RM; Borgmeier A; Flentje M; Willner J; Schmidt M; Manegold C; Bramlage P; Debus J
    Clin Lung Cancer; 2010 Jan; 11(1):45-50. PubMed ID: 20085867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non-small-cell lung cancer.
    Harada H; Nishio M; Murakami H; Ohyanagi F; Kozuka T; Ishikura S; Naito T; Kaira K; Takahashi T; Horiike A; Nishimura T; Yamamoto N
    Clin Lung Cancer; 2013 Jul; 14(4):440-5. PubMed ID: 23540866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer.
    Dilling TJ; Extermann M; Kim J; Thompson LM; Yue B; Stevens CW; Antonia S; Gray J; Williams C; Haura E; Pinder-Schenck M; Tanvetyanon T; Kim S; Chiappori A
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):828-33. PubMed ID: 25216856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term survival results for patients with locally advanced, initially unresectable non-small cell lung cancer treated with aggressive concurrent chemoradiation.
    Langer CJ; Curran WJ; Keller SM; Catalano RB; Litwin S; Blankstein KB; Haas N; Campli SN; Comis RL
    Cancer J Sci Am; 1996; 2(2):99-105. PubMed ID: 9166507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twelve-year follow-up of trimodality therapy for stage IIIA non-small cell lung cancer.
    Weitberg AB; Liu L; Yashar J; Glicksman AS
    J Exp Clin Cancer Res; 2001 Sep; 20(3):335-40. PubMed ID: 11718211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).
    Katakami N; Tada H; Mitsudomi T; Kudoh S; Senba H; Matsui K; Saka H; Kurata T; Nishimura Y; Fukuoka M
    Cancer; 2012 Dec; 118(24):6126-35. PubMed ID: 22674529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer.
    Iwasaki Y; Ohsugi S; Natsuhara A; Tsubokura T; Harada H; Ueda M; Arimoto T; Hara H; Yamada T; Takesako T; Kohno K; Hosogi S; Nakanishi M; Marunaka Y; Nishimura T
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):735-41. PubMed ID: 16565832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer.
    Park SH; Choi SJ; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Cho EK; Shin DB; Hoon Lee J
    Cancer; 2007 Feb; 109(4):732-40. PubMed ID: 17211861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504.
    Gandara DR; Chansky K; Albain KS; Leigh BR; Gaspar LE; Lara PN; Burris H; Gumerlock P; Kuebler JP; Bearden JD; Crowley J; Livingston R;
    J Clin Oncol; 2003 May; 21(10):2004-10. PubMed ID: 12743155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
    Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
    Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral vinorelbine and cisplatin with concurrent radiotherapy after induction chemotherapy with cisplatin and docetaxel for patients with locally advanced non-small cell lung cancer: the GFPC 05-03 study.
    Descourt R; Vergnenegre A; Barlesi F; Lena H; Fournel P; Falchero L; Berard H; Hureaux J; Le Caer H; Chavaillon JM; Geriniere L; Monnet I; Chouabe S; Robinet G;
    J Thorac Oncol; 2011 Feb; 6(2):351-7. PubMed ID: 21164367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.
    Yang YJ; Park JC; Kim HK; Kang JH; Park SY
    Anticancer Res; 2013 May; 33(5):2115-22. PubMed ID: 23645763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer.
    Cardenal F; Arnaiz MD; Morán T; Jové J; Nadal E; Porta R; Solé JM; Brao I; Palmero R; Fuentes R; Núñez I; Caveda E; Cassinello A
    Lung Cancer; 2011 Oct; 74(1):69-74. PubMed ID: 21353323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent chemoradiotherapy followed by consolidation chemotherapy with bi-weekly docetaxel and carboplatin for stage III unresectable, non-small-cell lung cancer: clinical application of a protocol used in a previous phase II study.
    Saitoh J; Saito Y; Kazumoto T; Kudo S; Yoshida D; Ichikawa A; Sakai H; Kurimoto F; Kato S; Shibuya K
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1791-6. PubMed ID: 21601375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
    Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
    Azuma K; Sasada T; Kawahara A; Hattori S; Kinoshita T; Takamori S; Ichiki M; Imamura Y; Ikeda J; Kage M; Kuwano M; Aizawa H
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):565-73. PubMed ID: 19123003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin-docetaxel induction plus concurrent 3-D conformal radiotherapy and weekly chemotherapy for locally advanced non-small cell lung cancer patients: a phase II trial.
    Poudenx M; Bondiau PY; Chamorey E; Venissac N; Otto J; Pourel N; Castelnau O; Tessier E; De Surmont Salasc B; Berdah JF; Pop D; Michel C; Mouroux J
    Oncology; 2012; 83(6):321-8. PubMed ID: 22986621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.